ChinaDaily Briefs

Daily Brief China: CGN New Energy Holdings, Sichuan Baicha Baidao Industrial, Sinopharm Group Co Ltd H, Cosco Shipping Energy Transportation Co. Ltd. (H) and more

In today’s briefing:

  • CGN New Energy (1811 HK): Takeover Rumours
  • Baicha Baidao IPO: The Bear Case
  • Sinopharm Group (1099 HK): Sequential Recovery in 4Q23; Bleak Near-Term Outlook
  • Cosco Shipping Energy 1138.HK – Higher for Longer


CGN New Energy (1811 HK): Takeover Rumours

By David Blennerhassett

  • Another week, another rumoured (from Bloomberg) takeover. This time it’s for clean energy play CGN New Energy Holdings (1811 HK).
  • Back in 2020, CGN was subject to a potential privatisation from its SOE-parent – see CGN New Energy: The Latest SOE Clean Energy Play – but it failed to materialise.
  • A couple of years back, a “valuation system with Chinese characteristics” had the media discussing whether this implied a premium for SOEs and companies aligned with national goals.

Baicha Baidao IPO: The Bear Case

By Arun George

  • Sichuan Baicha Baidao Industrial (SCBCBDID CH), a leading freshly made tea drinks company, will launch an HKEx IPO to raise US$300 million next week, according to press reports.
  • In Baicha Baidao IPO: The Bull Case, we highlighted the key elements of the bull case. In this note, we outline the bear case.
  • The bear case rests on pedestrian store KPIs, unsustainable historical growth rates, declining contract liabilities, and margin pressure reflecting a fiercely competitive market.

Sinopharm Group (1099 HK): Sequential Recovery in 4Q23; Bleak Near-Term Outlook

By Tina Banerjee

  • Sinopharm Group Co Ltd H (1099 HK) reported YoY and sequential growth in revenue and net profit in 4Q23. However, outlook for the sector remains bleak in near-term.
  • Last year, Sinopharm’s distribution business was impacted by anti-corruption campaign. The momentum of the campaign continues in this year also. This lowers conviction toward improving performance in 1H24 at least.
  • Despite of mid-single digit revenue growth, Sinopharm’s margin remains stagnant or is declining. Sinopharm still earns more than 70% revenue from low margin earning pharmaceutical distribution business.

Cosco Shipping Energy 1138.HK – Higher for Longer

By Rikki Malik

  • The Supply/ Demand imbalance in tankers will persist for longer, supporting earnings
  • A beneficiary of increased global tensions and higher oil and gas prices
  • Proposed Stock option scheme incentives management in the right way

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars